Skip to main
MNKD
MNKD logo

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp's ongoing development of its orphan lung pipeline presents significant opportunities for long-term diversification and revenue growth, enhancing its overall financial outlook. The company’s strategic focus on marketing and education aims to improve the uptake of its products, particularly Afrezza and Tyvaso DPI, which are poised to capture market share and drive serviceable revenues across diabetes and pulmonary diseases. Additionally, the potential approval of the Furoscix auto-injector offers a considerable value driver, further solidifying MannKind's position in the biopharmaceutical landscape.

Bears say

MannKind Corp faces significant challenges that contribute to a negative outlook regarding its stock performance. The recent approval of a competitive product by SQ Innovation, combined with potential third-party challenges and vulnerabilities in intellectual property protection, could adversely impact MannKind's market position and sales. Additionally, delays in commercialization resulting from negative trial outcomes or regulatory issues could further limit the company's prospects and revenue potential in an already competitive landscape.

MannKind (MNKD) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 6 analysts, MannKind (MNKD) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.